Biotech Special edition

Welcome to interactive presentation, created with Publuu. Enjoy the reading!

Biotech

is building a

better world

Jean Peccoud talks cyberbiosecurity

Join the Fashion for Good movement

Biotechnology

special edition

January 2018

The Next Evolution

For the past 75 years, Kerry has evolved with the market trends in cell culture. As our

customers’ needs changed we have expanded our product portfolio to encompass

technologies needed to meet the evolving needs of the bio-pharma market globally.

AmpliCHO CD medium is our latest evolution.

AmpliCHO CD medium is a completely chemical chemically-defined medium that

does not contain supplements. It is optimized for extended growth and enhanced

recombinant protein production for CHO suspension cultures.

The benefits of using AmpliCHO CD medium:

● Significantly higher titers

● Low osmolality

● Extended viable density and cell viability

● Animal component free (ACF)

● Compatible with complex, defined, and CD supplements and feed

Chemically Defined Medium | Supplement Systems | Defined Supplements | Hydrolyzed Proteins | Yeast Extracts

Learn more at Kerry.com

CONTACT

Newsdesk: editorial@innovatorsmag.com

Advertising: advertising@innovatorsmag.com

Reception: +44 (0)141 570 0029

150 Central Chambers, 11 Bothwell St | Glasgow | Scotland | innovatorsmag.com | @innovatorsmag

iotechnology is transforming how industries and

societies operate. Just about every sector is feeling the

efect. And in this special biotech edition, we take a

look at some of the areas where it is making an impact,

including fashion; food; and the UN Sustainable

Development Goals (SDGs).

Professor Jean Peccoud, Abell Chair in Synthetic Biology at

Colorado State University, also shares his insight and advice on

the hot topic of cyberbiosecurity.

And I wholeheartedly agree with the organisers of the

triennial ACHEMA trade show - the world forum for the process

industries, in labelling Innovators Magazine the ‘perfect ft’ to

be the ofcial publishers of its ‘biotech for chemistry’ magazine.

Read more on the role the ‘biotech for chemistry’ theme will

play at ACHEMA 2018, which will welcome around 170,000

professionals to Frankfurt this summer.

As well as being sent to a targeted biotechnology audience

digitally, this magazine is being distributed to delegates

attending the fourth annual conference of Scotland’s

Industrial Biotechnology Innovation Centre (IBioIC) in

Glasgow. It is the third year we have been a media partner

with the conference, which has quickly established itself

as one of the most infuential in Europe. We have a special

feature section by IBioIC inside.

I am also happy to announce we are continuing our

collaboration with Newsquest International, on the annual

Global Game Changers awards. The

platform recognises and showcases

the achievements of cross-sectoral

innovators contributing to the SDGs.

It will be held in Glasgow later this

year, and then in London in 2019.

We’ll have more details on this on our

website within the next few weeks.

IN THIS ISSUE

CORE TEAM

Welcome

Iain

Robertson

Editor

Biotechnology & …

2 Cyberbiosecurity

4 Fashion

6 The UN Sustainable

Development Goals

10 Women

12 Food

14 Chemistry

16 Trends

Q&A

18 Adeel Aslam, Bouygues

Energies & Services

IBioIC feature

22 Industrial Biotechnology

Innovation Centre (IBioIC)

conference messages

And…

28 BIO conference returns to

Philadelphia

Editor | Iain Robertson

Partnerships | Susan Robertson

Digital | Ryan McFadyen

Design | Blair Carrick

News & Features | Carlotta De Toni

Operations | Gillian Greig

Innovators Magazine accepts no responsibility for any efects from errors or omissions. All material is copyright and reproduction is not

permitted without express permission. All rights reserved.

It’s time to talk about

cyberbiosecurity

Can you give us an

overview of the emerging

field of cyberbiosecurity?

The feld is so new that its

boundaries are very much in fux.

Some people would include standard

cybersecurity or physical security of life

science facilities. Others tend to include

cybersecurity of clinical data or human

genomics database in this area. People

like the sound bite and often associate

it with a number of other existing felds.

Personally, I have a DNA-centric notion

of this feld. I am focused on

understanding how can DNA synthesis,

DNA sequencing, and bioinformatics

create new vulnerabilities and new risk

management strategies.

What are the risks and

opportunities in the

digitisation of DNA?

Keeping the digitisation of

personal genomics data aside, as

this a diferent issue - in biotechnology,

the main risk is that we don’t really

understand the implications of this

trend. As biologists, we still associate

DNA with a natural molecule carrying

the genetic information of living

organisms. Its digital representation is

just a convenience to help work with

the natural organisms. This is not unlike

the early days of software when

computer programs were bundled with

computing hardware. You can think of

digital DNA as software inspired by

natural DNA, like computer programs

are somewhat reminiscent of natural

languages. This analogy with the

evolution of software radically changes

perspective. Digital DNA becomes

man-made. It becomes the expression

of an intent. It becomes more valuable

than the biological samples that

inspired it. That’s the opportunity.  

What do you feel are the

key issues that biologists

should be aware of?

Biologists need to develop a

culture of security in their labs.

Most of us are incredibly naive when we

walk into our labs. Biological processes

have a mind of their own. They tend to

be more complicated, slower, and less

reproducible than other felds of

engineering. That reality gives

biologists a high tolerance for

anomalies. In this context, we tend to

attribute anomalies to the complexity

of biological processes. Without

becoming paranoid, we need to learn

to consider the possibility that our

processes behave in unexpected

ways for other reasons than

biological complexity. Human

errors, accidents, software

bugs, or people trying to hurt

us can also compromise what

we are trying to do in our labs.

What can be done

to create the best

possible strategy for

the future?

Talking about the issue

like we do in this

conversation is certainly a

step in the right direction.

Denial is not a very strong

security posture. By

discussing these issues, we

create an awareness that

increases our security. 

How can

people connect

and contribute to

the existing work in

this area?

They can reach out

to me as we are

putting together a centre

that will be a forum to

exchange on these issues.

Innovators Magazine caught up with Professor

Jean Peccoud, Abell Chair in Synthetic Biology at

Colorado State University, to find out why…

BIG THREATS

Te exposure of every

organisation is unique. So,

it is difcult to generalise.

However, we can think of

threats at the national level

that would impact every life

science organisation in one

way or another.

A biosecurity incident

with national security

implications would be

catastrophic. If you

remember the policy

implications of the 2001

Anthrax incident, then it is

not hard to imagine what the

policy implications would be

of a biosecurity incident with

roots in emerging

technologies to manipulate

DNA. Te industry as a

whole could face a major

public relations crisis that

would dramatically change

the perception of these new

technologies. We could

end up in a very

diferent regulatory

environment that would

hinder the development of

the bioeconomy.

Compromising

manufacturing capacity.

Incidents afecting industrial

infrastructures are likely

expensive because of the scale

of manufacturing operations.

In many scenarios

recommissioning a

compromised infrastructure

may take months. Tis can

have signifcant disruption on

the availability of life-saving

drugs for instance.

Loss of competitive

advantage and thef of

intellectual property is also a

source of concern. Te

biotechnology supply chain is

getting more global. In many

cases the choice of vendors

and business partners is

driven by short-term cost

reduction without always

considering the

consequences of these choices

on long-term competitiveness.

KEY ACTIONS

Acknowledge the

evolving security

landscape of the life sciences.

Analysing risks is not

pleasant because nobody

likes to discuss their

vulnerabilities. However, the

discomfort of risk analysis is

nothing compared to

managing the crisis of a

security breach.

Education and

awareness throughout

the organisation are essential.

Analysing the risk should not

be the exclusive responsibility

of the scientists working in

the lab. Tis cannot happen

without a strong mandate

from the board of directors

and executives. It is also

important to involve non-

technical parts of the

organisations like

procurement, IT, and

risk management.

Implementing a

security policy is ofen

regarded as an annoyance

that hinders productivity and

negatively impacts an

organisation’s proftability. It

is therefore important to

thoroughly understand the

economics of the risks to

prioritise risk management

policies. Eforts should focus

frst on inexpensive policies

that will positively impact the

bottom line. It is essential to

the sustainability of the efort.

Follow

@peccoud

SHUTTERSTOCK

e are a global platform for

innovation, made possible

through collaboration and

community. With an open invitation

to the entire apparel industry, Fashion

for Good convenes brands, producers,

retailers, suppliers, non-proft

organisations, innovators and funders

united in their shared ambition.

At the core of Fashion for Good is our

innovation platform. Through our Fashion

for Good-Plug and Play Accelerator,

we work with one of the world’s

largest technology accelerators to give

promising startup innovators the funding

and expertise they need in order to

grow. Our Scaling Programme supports

innovations that have passed the proof-

of-concept phase, with a dedicated team

that ofers bespoke support and access to

expertise, customers and capital. Finally,

our Good Fashion Fund (in development)

will catalyse access to fnance where

this is required to shift at scale to more

sustainable production methods.

Additionally, Fashion for Good acts as a

convener for change. From its frst hub in

Amsterdam, it houses a Circular Apparel

Community co-working space, creates

open-source resources like its Good

Fashion Guide, and welcomes visitors

to join a collective movement to make

fashion a force for good.

Fashion for Good’s programmes are

supported by Philanthropic Partner C&A

Foundation and Corporate Partners C&A,

Galeries Lafayette Group and Kering.

Fashion for Good is the global initiative

that is here to make all fashion good.

Colorifx solves the

environmental problems

associated with the production

of pigments and their transfer

to fabrics and garments.

We do this using synthetic

biology, allowing engineered

microorganisms to produce the

pigments for us. Furthermore,

the microorganisms are

used to transfer and fx the

pigments directly to the

fabric, thereby improving

dye transfer efciency and

reducing water and energy

consumption accordingly. The

net efect is a beautifully dyed

fabric or garment but without

the environmental damage

associated with traditional dye

production and transfer.

Dr David Nugent | Colorifx

Limited | colorifx.com

sustainability

CALL-TO-ACTION

FOR BIOTECHS

Through Fashion for Good’s

innovation platform, we support

startups and companies with the

potential to change the fashion

industry for good, and we are

particularly interested in the

biotechnology sphere. If you are

an entrepreneur with a relevant,

replicable and scalable innovation,

please visit fashionforgood.com to

learn more about our work and apply

for the Fashion for Good-Plug and Play

Accelerator if you fnd there is a ft.

Dr David Nugent, Colorifix & Emma

Scarf, Fashion for Good, Amsterdam.

Image credit Rosa van Ederen

We live in a world of fast fashion and disposable clothing and most people think this

is a disaster. They are working on recycling and circular fashion and want to change

the behaviour of seven billion people. This represents an incredible opportunity.

We have an entire generation of people who now expect to own a garment for a

year, maybe two, before disposing it and buying something new. With the right

type of materials they can be custom-designed to meet that life cycle. MycoTEX is a

100% biodegradable material based on mycelium, the root of mushrooms. We have

developed a technology and technique to create a sustainable fabric and made

prototypes with this material and the 3D modelling process. MycoTEX is sustainably

grown in a lab, so we don’t need expensive farmland or its seasonal infuences.

We use less water and no chemicals or pesticides. MycoTEX ofers a shorter

supply chain, limits transport use and allows for an entirely new way of designing

garments. After wearing you can simply bury your garment in the ground and it will

decompose. Aniela Hoitink | NEFFA | nefa.nl

MycoTEX-diagonal

A new online network invites innovators,

startups, companies and others to

collaborate on solutions for some of the

world’s greatest challenges. The first theme

is water scarcity, and a call from UNICEF is

among the first tasks. By Daniel Cardinali

he UN’s 17 Sustainable

Development Goals (SDGs)

are a roadmap for sustainable

development, covering the social,

economic and environmental challenges

which face the world today. They are

ambitious and important goals. From

tackling the problem of clean drinking

water to developing sustainable

healthcare solutions for everyone, biotech

has the potential to make

a real impact. But where

do we start? The SDGs are

too complex to be solved

by any one individual

or organisation. The

consensus is that we must

collaborate to solve these

challenges. We need

collaboration to bring fresh ideas and

new perspectives. Working with people

from diferent disciplines leads to new

ways of thinking, better solutions and

faster progress.

HelloScience, an open innovation

community created by Novozymes,

aims to address exactly this. It

provides an online network for

researchers, entrepreneurs, NGOs,

companies and startups to collaborate

in tackling the SDGs together. The

driving force is the ambition to

transform our world for the better.

HelloScience is our attempt to fnd new

and unlikely partnerships by empowering

startups and researchers to develop their

technologies and applications faster.

Everyone is welcome.

Biotechs urged to tackle

global challenges

Everybody with an interest can

suggest ideas on the HelloScience

platform (helloscience.io). By

posting ideas or solutions to a

challenge, you gain access to

a network of researchers and

innovators to collaborate with.

Novozymes will give

enzyme and microorganism

samples to the most promising

ideas and will also provide access to

industry and investment experts.

HelloScience defnes diferent

themes for collaboration. The frst

theme is water, inspired

by the sixth SDG: clean water

and sanitation.

Currently the platform has fve

challenges related to the theme:

innovation for better fltering,

reduction of sludge, recovery of

phosphates in waste, an open

challenge on clean water and a

challenge from UNICEF to develop

a device to aid in the detection of

E. coli bacteria in water.

So far, six solutions posted on

HelloScience are being developed

through collaboration with

Novozymes. One example is an

innovative and sustainable way to

reduce sludge. The solution consists

of using enzymes to treat sludge

waste. The byproducts are water and

a solid biopellet, which can be used

to generate energy.

The biopellet solution comes

from an Argentinian biotech

company, which specialises in

biomining. Other examples of

successful solutions come from

a life science company in India, a

nanotechnology startup from

the Netherlands and a lecturer

from the University of

Queensland in Australia.

The challenges will run for a

specifc time, and new SDG themes

will be added soon.

Please go to HelloScience.io and

join us in solving some of the

world’s greatest challenges.

Daniel Cardinali is Head of

HelloScience at Novozymes

How

it works

Daniel

Cardinali

Working with people from

different disciplines leads

to new ways of thinking,

better solutions and faster

progress.

Novozymes is a Danish

biotech company and the

world’s largest maker of enzymes

and microorganisms. The company

sells its products to more than 40

diferent industries, where they

replace chemicals and accelerate

production processes.

Enzymes are widely used in

laundry and dishwashing

detergents where they remove

stains and enable low-temperature

washing and concentrated

detergents. Other enzymes improve

the quality of bread, beer and wine,

or increase the nutritional value of

animal feed. Enzymes are also used

in the production of biofuels where

they turn starch or cellulose from

biomass into sugars which can be

fermented to ethanol.

Like enzymes, microorganisms

have natural properties that can be

used in industry.

Novozymes supplies

microorganisms that can increase

crop yields in agriculture,

improve animal health and

nutrition, and treat wastewater.

Novozymes was founded in 2000

in a demerger from pharmaceutical

company Novo Nordisk.

Novozymes’ roots date back

to the 1920s when Novo

Terapeutisk Laboratorium and

Nordisk Insulinlaboratorium were

established in Copenhagen.

Enzyme production began in 1941.

Novozymes

Say Hello...

to the HelloScience

community on social media:

@HelloScienceIO

HelloScience

Similar to eforts made by the

biotech industry, the Consortium

for Afordable Medical Technologies

(CAMTech), based at Massachusetts

General Hospital Global Health, has

focused its eforts on addressing

the SDGs by creating shared value

in global health. CAMTech identifes

pressing clinical needs from the feld,

crowdsources innovative solutions

and accelerates the cycle from idea to

patient impact. Since 2012, CAMTech

has leveraged its neutral broker status

to convene a diverse and collaborative

set of stakeholders with a goal of

impactful innovation, bringing

together over 4,370 innovators, 650

mentors and 730 organisations to

design more than 830 innovations.

Using innovation to mitigate

infectious disease outbreaks and

improve maternal and child health

has proved impactful. CAMTech

hackathons, 48-hour events in

which a group of curated individuals

from diferent backgrounds come

together to drive innovation in

healthcare, have allowed clinicians,

public health professionals, engineers

and entrepreneurs to act as frst

responders to infectious disease

outbreaks like Ebola and Zika.

Several hackathons, bootcamps and

innovation awards have also focused

on improving maternal and child

health and closing the gender gap in

medtech.

During CAMTech’s 2014 Stop Ebola

hackathon, innovators designed an

Ebola Treatment Unit that integrates

UN’s 2030

goals should

spark a

conversation

ach of the 17 SDGs outline

strategies to end extreme poverty,

inequality and climate change by

2030. Building on the progress made

by the Millennium Development Goals,

the SDGs prioritise people, planet,

prosperity, peace and partnership to

build a more sustainable world. The

SDGs implicate all countries and all

stakeholders and call upon industry

leaders to address these initiatives.

Two years since the United Nations

implemented the SDGs, the fourth

annual Industrial Biotechnology

Innovation Centre (IBiolC) conference

in Glasgow, which convenes over 400

biobased professionals, academics and

students, is an opportunity to further

these conversations. IBioIC’s mission

is ‘to help businesses large and small

increase the pace of innovation’. The

biotech industry has the potential to

make signifcant contributions to the

SDGs through the use of innovation,

entrepreneurship and sustainable

resources to advance population health.

Using a biotech approach to advance

population health is crosscutting and

aligns with nearly all 17 SDGs.

By Nicholas Diamond

Innovators

simulate an Ebola

Treatment Unit

during CAMTech’s

2014 Stop Ebola

Hackathon.

The RESCUE

Team won for

its optimised

Ebola Treatment

Unit, which is

mobile, scalable

and integrates

culturally sensitive

infection control

and training

methods in rural

settings.

At the 2017 United

Nations General

Assembly, Dr. Data

Santorino, CAMTech

Uganda Country

Manager, presents a

demo of the Augmented

Infant Resuscitator (AIR)

device, which emerged

from CAMTech’s first

hackathon in 2012.

Randomised control

trials demonstrated

that the time needed

to achieve effective

ventilation was reduced

in half when using the

AIR device, and the

duration of effective

ventilation increased by

more than 50%.

In January 2016,

193 world leaders at

the United Nations

implemented the

17 Sustainable

Development Goals

(SDGs) as a part of

the 2030 Agenda

for Sustainable

Development.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Made with Publuu - flipbook maker